PMID- 29593010
OWN - NLM
STAT- In-Data-Review
LR  - 20180602
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 27
IP  - 6
DP  - 2018 Jun
TI  - Differences in Breast Cancer Survival by Molecular Subtypes in the United States.
PG  - 619-626
LID - 10.1158/1055-9965.EPI-17-0627 [doi]
AB  - Background: Although incidence rates of breast cancer molecular subtypes are well
      documented, effects of molecular subtypes on breast cancer-specific survival
      using the largest population coverage to date are unknown in the U.S. POPULATION:
      Methods: Using Surveillance, Epidemiology and End Results cancer registry data,
      we assessed survival after breast cancer diagnosis among women diagnosed during
      2010 to 2013 and followed through December 31, 2014. Breast cancer molecular
      subtypes defined by joint hormone receptor [HR, estrogen receptor (ER) and/or
      progesterone receptor (PR)] and HER2 status were assessed. Multiple imputation
      was used to fill in missing receptor status. Four-year breast cancer-specific
      survival per molecular subtypes and clinical/demographic factors were calculated.
      A Cox proportional hazards model was used to evaluate survival while controlling 
      for clinical and demographic factors.Results: The best survival pattern was
      observed among women with HR(+)/HER2(-) subtype (survival rate of 92.5% at 4
      years), followed by HR(+)/HER2(+) (90.3%), HR(-)/HER2(+) (82.7%), and finally
      worst survival for triple-negative subtype (77.0%). Notably, failing to impute
      cases with missing receptor status leads to overestimation of survival because
      those with missing receptor status tend to have worse prognostic features.
      Survival differed substantially by stage at diagnosis. Among de novo stage IV
      disease, women with HR(+)/HER2(+) subtype experienced better survival than those 
      with HR(+)/HER2(-) subtype (45.5% vs. 35.9%), even after controlling for other
      factors.Conclusions: Divergence of survival curves in stage IV HR(+)/HER2(+)
      versus HR(+)/HER2(-) subtype is likely attributable to major advances in
      HER2-targeted treatment.Impact: Contrary to conventional thought, HR(+)/HER2(+)
      subtype experienced better survival than HR(+)/HER2(-) in advanced-stage disease.
      Cancer Epidemiol Biomarkers Prev; 27(6); 619-26. (c)2018 AACR.
CI  - (c)2018 American Association for Cancer Research.
FAU - Howlader, Nadia
AU  - Howlader N
AD  - Surveillance Research Program, Division of Cancer Control and Population
      Sciences, National Cancer Institute, Bethesda, Maryland. howladern@mail.nih.gov.
FAU - Cronin, Kathleen A
AU  - Cronin KA
AD  - Surveillance Research Program, Division of Cancer Control and Population
      Sciences, National Cancer Institute, Bethesda, Maryland.
FAU - Kurian, Allison W
AU  - Kurian AW
AD  - Stanford University School of Medicine, Stanford, California.
FAU - Andridge, Rebecca
AU  - Andridge R
AD  - The Ohio State University College of Public Health, Columbus, Ohio.
LA  - eng
PT  - Journal Article
DEP - 20180328
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American
      Association for Cancer Research, cosponsored by the American Society of
      Preventive Oncology
JID - 9200608
EDAT- 2018/03/30 06:00
MHDA- 2018/03/30 06:00
CRDT- 2018/03/30 06:00
PHST- 2017/07/11 00:00 [received]
PHST- 2017/08/30 00:00 [revised]
PHST- 2018/03/20 00:00 [accepted]
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2018/03/30 06:00 [medline]
PHST- 2018/03/30 06:00 [entrez]
AID - 1055-9965.EPI-17-0627 [pii]
AID - 10.1158/1055-9965.EPI-17-0627 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626. doi:
      10.1158/1055-9965.EPI-17-0627. Epub 2018 Mar 28.